QIAGEN(QGEN)

Search documents
QIAGEN N.V. announces successful placement of new net share settled convertible bonds
GlobeNewswire News Room· 2024-09-03 15:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN") announces certain terms of the new senior, unsecured net sha ...
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
GlobeNewswire News Room· 2024-09-03 06:36
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. VENLO, The Netherlands, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Managing Board and Supervisory Board of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") ...
Reasons to Retain QIAGEN Stock in Your Portfolio Now
ZACKS· 2024-08-27 14:55
QIAGEN N.V.'s (QGEN) growth is backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to macroeconomic volatilities and currency fluctuations, which can adversely affect its financial results. Year to date, this Zacks Rank #3 (Buy) stock has risen 0.9% compared with 10.5% growth of the industry. The S&P 500 composite has witnessed an 18.1% rise in ...
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
ZACKS· 2024-08-22 14:55
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Z ...
QIAGEN(QGEN) - 2024 Q2 - Quarterly Report
2024-08-02 01:07
Exhibit 99.7 QIAGEN N.V. IFRS Annual Report 2023 QIAGEN N.V. | IFRS Annual Report 2023 Overview Management Report Corporate Governance Financial Statements Appendices Page 2 Overview Table of Contents | --- | --- | --- | --- | |-------|------------------------------------------------------------|-------|-------------------------------------------------| | | | | Consolidated Financial Statements | | | Overview | 172 | Consolidated Balance Sheets | | 3 | Common Shares | 174 | Consolidated Income Statements | ...
QIAGEN(QGEN) - 2024 Q2 - Earnings Call Transcript
2024-08-01 19:04
Qiagen N.V. (NYSE:QGEN) Q2 2024 Earnings Call Transcript Q2 2024 Earnings Conference Call August 1, 2024 9:00 AM ET Company Participants John Gilardi - Investor Relations Thierry Bernard - Chief Executive Officer and Managing Director Roland Sackers - Chief Financial Officer and Managing Director Conference Call Participants Catherine Schulte - Baird Michael Ryskin - Bank of America Jack Meehan - Nephron Research Dan Arias - Stifel Odysseas Manesiotis - Berenberg Bank Douglas Schenkel - Wolfe Research Patri ...
QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash
ZACKS· 2024-08-01 13:40
QIAGEN N.V.'s (QGEN) second-quarter 2024 adjusted earnings per share (EPS) were 55 cents, the same at the constant exchange rate (CER). The reported figure increased 7.8% from the 2023 comparable figure and topped the Zacks Consensus Estimate by 5.8%. The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others. On a GAAP basis, the lo ...
Compared to Estimates, Qiagen (QGEN) Q2 Earnings: A Look at Key Metrics
ZACKS· 2024-08-01 01:05
For the quarter ended June 2024, Qiagen (QGEN) reported revenue of $496.35 million, up 0.3% over the same period last year. EPS came in at $0.55, compared to $0.53 in the year-ago quarter. The reported revenue represents a surprise of +0.45% over the Zacks Consensus Estimate of $494.13 million. With the consensus EPS estimate being $0.52, the EPS surprise was +5.77%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...
Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates
ZACKS· 2024-08-01 00:40
Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.77%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.44 per share when it actually produced earnings of $0.46, delivering a surprise of 4.55%. Over the last four quarters, the ...
QIAGEN delivers solid performance and exceeds outlook for Q2 2024
Newsfilter· 2024-07-31 20:06
Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supportin ...